$NSPR 1000% coming here
nspireMD Announces Regulatory Approval of CGuard EPS in India; Signs Agreement with Leading Indian Medical Device DistributorFont size: A | A | A
8:55 AM ET 1/3/18 | GlobeNewswire
RELATED QUOTES
12:35 PM ET 1/4/18
Symbol Last % Chg
NSPR
0.13 -2.81%
Real time quote.
InspireMD Announces Regulatory Approval of CGuard EPS in India; Signs Agreement with Leading Indian Medical Device Distributor
TEL AVIV, ISRAEL, Jan. 03, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received regulatory approval for the CGuard(TM) Embolic Prevention System (EPS) in India. The approval was granted by India's Central Drugs Standard Control Organisation within the Ministry of Health & Family Welfare. The Company also announced it signed Hester Diagnostics Pvt. Ltd. as its exclusive distributor in India. This partnership follows similar distribution agreements across Asia, including Hong Kong, Taiwan, Australia, New Zealand and Vietnam.
Hester Diagnostics brings over 25 years of distribution and marketing experience in India, including medical devices, diagnostic kits and a wide range of additional products for the healthcare industry. Hester works with many of the leading medical device companies in the United States, Europe and Japan covering clinical specialties that include interventional cardiology, interventional neuroradiology, and interventional radiology.
Sanjiv Gandhi, Managing Director of Hester Diagnostics, commented, "We are excited to partner with InspireMD, given the extensive clinical data illustrating the safety advantages of CGuard(TM) EPS. We are now gearing up and look forward to commencing the formal commercial launch of the product."
"The approval of CGuard(TM) EPS in India marks another commercial milestone as we continue to expand our global footprint," said Agustin Gago, EVP and Chief Commercial Officer of InspireMD. "We are excited to partner with Hester Diagnostics, which brings an impressive track record launching medical devices in India and to the key clinical specialties that treat carotid artery disease."
